
Quizartinib, a selective FLT3 inhibitor, maintains anti-leukaemic activity
A study published in the journal Oncotarget has reported a preclinical study, which has characterised the binding…
A study published in the journal Oncotarget has reported a preclinical study, which has characterised the binding…